shadow_tr

The People of Tulane Cancer Center Research


Yan DongYan Dong, Ph.D.
Associate Professor, Department of Structural and Cellular Biology
Tulane Cancer Center Program Member

Contact Information
Email: ydong@tulane.edu
Phone: 504-988-4761
Address: 1430 Tulane Ave., Box SL-49, New Orleans, LA 70112-2699


Biographical Narrative

Dr. Dong received her Ph.D. in experimental pathology from the State University of New York at Buffalo in 2000. From 2000 - 2002, she was a postdoctoral fellow in cancer chemoprevention at Roswell Park Cancer Institute. She became a research assistant professor in 2002 and an assistant professor in 2005 in the Cancer Chemoprevention Department. In November 2007, Dr. Dong joined the faculty of Tulane University School of Medicine as an assistant professor in the Department of Structural and Cellular Biology.

Research Interests
The major focuses of the laboratory are to understand the mechanisms involved in resistance of prostate cancer to hormone (androgen-deprivation) therapy and to develop effective approaches to overcome resistance to hormone therapy. Hormone therapy has been shown to lead to upregulated expression of androgen receptor splice variants, which lack the ligand-binding domain but remain constitutively active, in prostate cancer cells. The upregulation contributes to resistance to hormone therapy. Dr. Dong’s laboratory is currently characterizing the mechanisms by which these androgen receptor splice variants mediate therapy resistance, and developing agents to target these androgen receptor splice variants for prostate cancer therapy.

Selected Publications
R Gao, X Liu, B Cao, Y Zhan, Y Qi, H Zhang, Y Dong (2013) The Role of Selenium in Prostate Cancer Therapy. Chapter in Prostate Cancer Cells: Detection, Growth and Treatment, Nova Science Publishers, Inc, NY, p197-208

B Cao, X Liu, J Li, S Liu, Y Qi, Z Xiong, A Zhang, T Wiese, X Fu, J Gu, PS Rennie, O Sartor, BR Lee, C Ip, L Zhao, H Zhang, and Y Dong. (2013) 20(S)-Protopanaxadiol-aglycone Downregulation of the Full-length and Splice Variants of Androgen Receptor. International Journal of Cancer, 132, 1277–1287. PMID: 22907191

Y Zhan, B Cao, Y Qi, S Liu, Q Zhang, W Zhou, D Xu, H Lu, O Sartor, W Kong, H Zhang, and Y Dong. (2013) Methylselenol Prodrug Enhances MDV3100 Efficacy for Treatment of Castration-Resistant Prostate Cancer. International Journal of Cancer, 2013 Apr 11. doi: 10.1002/ijc.28202. [Epub ahead of print]. PMID: 23575870. Featured in “MDLinx”.

Alison Egan, Yan Dong, Haitao Zhang, Yanfeng Qi, Steven P Balk, Oliver Sartor. (2013) Castration-Resistant Prostate Cancer: Adaptive Responses in the Androgen Axis. Cancer Treatment Reviews, 2013 Sep 14. [Epub ahead of print]. PMID:24139549

Y Qi, X Fu, Z Xiong, H Zhang, SM Hill, BG Rowan, and Y Dong. (2012) Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer. Plos One, 7, e31539.

R Gao, L Zhao, X Liu, BG Rowan, M Wabitsch, DP Edwards, Y Nishi, T Yanase, Q Yu, Y Dong. (2012) Methylseleninic Acid is a Novel Suppressor of Aromatase Expression. Journal of Endocrinology, 212, 199–205. PMID: 22128327. - one of the top downloaded research articles from the journal website.

H Zhang, J Fang, D Yao, Y Wu, C Ip, and Y Dong. (2010) Activation of FOXO1 Is Critical for the Anticancer Effect of Selenium in Prostate Cancer Cells. Prostate, 70, 1265-1273. PMID: 20623629

S Liu, Y Qi, Y Ge, T Duplessis, BG Rowan, C Ip, H Cheng, PS Rennie, I Horikawa, AJ Lustig, Q Yu, H Zhang, and Y Dong. (2010) Telomerase as an important target of androgen-signaling blockade for prostate cancer treatment. Molecular Cancer Therapeutics, 9, 2016-2025. PMID: 20571066. Featured in the "MOLECULAR CANCER THERAPEUTICS Highlights: Selected Articles from This Issue."

Liu S, Zhang H, Zhu L, Zhao L, Dong Y. KLF4 is a novel mediator of selenium in growth inhibition. Molecular Cancer Research, 6:1, 2008.

Li S, Zhou Y, Wang R, Zhang H, Dong Y, Ip C. Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-akt and its downstream substrates. Molecular Cancer Therapeutics, 6:1031, 2007.

Zhang H, Wu Y, Malewicz B, Lu J, Li S, Marshall JR, Ip C, Dong Y. Augmented suppression of androgen receptor signaling by a combination of alpha-tocopheryl succinate and methylseleninic acid. Cancer, 107:2942, 2006.

Dong Y, Zhang H, Gao AC, Marshall JR, Ip C. Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to selenium inhibition of growth and cancer-specific biomarkers. Molecular Cancer Therapeutics, 4:1047, 2005.

Dong Y, Lee S, Zhang H, Marshall JR, Gao AC, Ip C. Prostate specific antigen (PSA) expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res, 64:19, 2004.

Dong Y, Zhang H, Hawthorn L, Ganther HE, Ip C. Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array. Cancer Research, 52:708, 2003.

 

1430 Tulane Ave, New Orleans, LA 70112 504-988-5187 medsch@tulane.edu